Healthcare

Business

Valley National Bancorp Beats Q4 Estimates on Strong Deposit Growth, Outlines Path for Margin Expansion

Valley National Bancorp (VLY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by robust core deposit growth and disciplined balance sheet management. The regional bank's leadership pointed to strategic tech investments and commercial loan demand as key pillars for its 2025 outlook.

Jan 30, 2026

Business

Beyond Jabil: Why This Market Darling May Disappoint, and a Digital Ad Play to Watch

While Jabil's stock has mirrored the S&P 500's recent gains, a closer look reveals underlying concerns over growth, profitability, and cash flow. We analyze the risks and spotlight a more compelling alternative in the digital advertising space.

Jan 30, 2026

Business

Geron Sees Price Target Cut to $3 by TD Cowen Ahead of Q4, But Buy Rating Stays

Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.

Jan 30, 2026

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Reed Jobs Launches $200M+ Venture Fund Aiming to Turn Cancer into a Manageable Condition

Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.

Jan 30, 2026

Business

Haemonetics Gains Analyst Backing After Strategic Vivasure Buyout

Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.

Jan 30, 2026

Business

Advocate Health Announces Major Compensation Overhaul, Boosting Minimum Wage and Benefits Across Six States

Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.

Jan 30, 2026

Business

Navigating the Giants: One Large-Cap Stock with Room to Run, and Two Facing Headwinds

While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.

Jan 30, 2026

Business

Waste Management's Q4: Cost Control and Margin Gains Counter Revenue Shortfall

Waste Management's fourth-quarter revenue fell short of Wall Street forecasts, yet the company demonstrated robust margin expansion through disciplined cost management and strategic integration of acquisitions, setting a firm foundation for its 2026 outlook.

Jan 30, 2026

Business

iRhythm Holdings Gains Wall Street Favor as Cardiac Monitoring Demand Surges

Morgan Stanley and Evercore ISI reaffirm bullish ratings on iRhythm, citing strong Q4 preliminary results and growth potential from its next-gen cardiac monitoring technology.

Jan 30, 2026

Business

Guggenheim Boosts Bruker Price Target to $58, Citing Strong Diagnostics Outlook

Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.

Jan 30, 2026

Business

Hedge Funds Bet Big on Insulet's Omnipod: Analysts See Over 40% Upside for Diabetes Tech Leader

Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.

Jan 30, 2026

Business

Piper Sandler Bullish on Stryker, Sees 17% Upside Fueled by New Robotic Tech

Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.

Jan 30, 2026

Business

Boston Scientific Gains Analyst Favor Following Penumbra Acquisition, Price Target Raised

Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.

Jan 30, 2026

Business

DexCom's Strong Q4 Preliminary Results and Ambitious 2026 Outlook Fuel Investor Optimism

DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.

Jan 30, 2026

Business

Analysts Trim Targets but See Steady Growth Ahead for Abbott Laboratories

Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.

Jan 30, 2026

Business

Edwards Lifesciences Gains Analyst Favor as Renewed Growth Cycle Takes Hold

Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.

Jan 30, 2026

Business

Medtronic's Growth Outlook Tempered by Survey on Renal Denervation Adoption

A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.

Jan 30, 2026

Business

Marsh & McLennan Beats Q4 Estimates as Digital and AI Investments Offset Market Pressures

The global professional services giant reported stronger-than-expected fourth-quarter results, with revenue climbing 8.7% to $6.60 billion. Strategic investments in digital infrastructure and artificial intelligence are credited for driving growth despite headwinds in insurance pricing.

Jan 30, 2026